Haemonetics (NYSE:HAE) announced today that it received FDA approval to expand the labeling for its Vascade MVP XL system.
NEW ORLEANS – Standard medical care seemed to be a better bet than a catheter-based procedure in high-risk patients with atrial fibrillation (Afib), according to the CLOSURE-AF study. The trial had a ...
At first glance, the results of the CLOSURE-AF study would seem to spell doom for left atrial appendage closure devices for patients at risk of stroke, but there is some noise in the signal, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results